PT  - JOURNAL ARTICLE
AU  - Kraay, Alicia N.M.
AU  - Nelson, Kristin N.
AU  - Zhao, Conan Y.
AU  - Demory, David
AU  - Weitz, Joshua S.
AU  - Lopman, Benjamin A.
TI  - Modeling serological testing to inform relaxation of social distancing for COVID-19 control
AID  - 10.1101/2020.04.24.20078576
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.24.20078576
4099  - http://medrxiv.org/content/early/2020/11/17/2020.04.24.20078576.short
4100  - http://medrxiv.org/content/early/2020/11/17/2020.04.24.20078576.full
AB  - Serological testing remains a passive component of the current public health response to the COVID-19 pandemic. Using a transmission model, we examined how serology can be implemented to allow seropositive individuals to increase levels of social interaction while offsetting transmission risks. We simulated the use of widespread serological testing in three metropolitan areas with different initial outbreak timing and severity characteristics: New York City, South Florida, and Washington Puget Sound. In our model, we use realistic serological assay characteristics, in which tested seropositive individuals partially restore their social contacts and act as immunological ‘shields’. Compared to a scenario with no intervention, beginning a mass serological testing program on November 1, 2020 was predicted to avert 15,000 deaths (28% reduction, 95% CrI: 0.4%-30.2%) in New York City, 3,000 (31.1% reduction, 95% CrI: 26.4%-33.3%) in South Florida and 10,000 (60.3% reduction, 95% CrI: 50.2%-60.7%) in Washington State by June 2021. In all three sites, widespread serological testing substantially blunted new waves of transmission. Serological testing has the potential to mitigate the impacts of the COVID-19 pandemic while also allowing a substantial number of individuals to safely return to social interactions and economic activity.Significance The SARS-CoV-2 pandemic led many countries to implement broadly impactful social distancing interventions. In the U.S., many measures are still partially in place. While these policies slowed the epidemic, they also caused substantial social and economic disruption. Here, we explore how using available serological assays to inform the individualized relaxation of social distancing could allow a gradual return to more normal levels of economic and social activity while mitigating public health risk. We find that large scale serological testing in major metropolitan areas has the potential to lower expected COVID-19 deaths, reduce peak health system burden to manageable levels, and also allow social distancing interventions to be substantially relaxed.Competing Interest StatementBAL reports grants and personal fees from Takeda Pharmaceuticals and personal fees from World Health Organization outside the submitted work.Funding StatementBAL and ANMK were supported by the Vaccine Impact Modelling Consortium; BAL and KNN were supported by NIH/NICHD R01 HD097175; BAL, KNN, and ANMK were supported by NIH/NIGMS R01 GM124280; JSW and DD were supported by Simons Foundation (Scope Award ID 329108); BAL was supported by NSF 2032084; JSW was supported by the Army Research Office (W911NF1910384); JSW and CYZ was supported by National Science Foundation (1806606, 1829636, and 2032082).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was exempt from IRB review because all data were publicly availableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTransmission model code and incidence data used are available at the links provided https://coronavirus.jhu.edu/map.html https://github.com/lopmanlab/Serological_Shielding https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/